4-MAPC, a 5α-Reductase Inhibitor, Reduces Rat Ventral Prostate Weight, DNA, and Prostatein Concentrations

    September 1991 in “ Journal of Andrology
    Husam Ghusn, T. C. Shao, Marcella Klima, Glenn R. Cunningham
    TLDR 4‐MAPC reduces rat prostate weight and prostatein levels.
    The study investigated the effects of 4‐MAPC, a 5α‐reductase inhibitor, on rat ventral prostate weight, DNA, and prostatein concentrations. Eight-week-old rats were treated with 4‐MAPC, with or without testosterone propionate (TP), for 14 days. Results showed that 4‐MAPC alone reduced ventral prostate weight by 37% and prostatein concentration by 45%, although the reduction in total DNA was not significant. The findings suggested that the reduction in prostate weight was primarily due to decreased synthetic activity and potential epithelial cell atrophy, rather than a reduction in cell number. Additionally, TP increased prostate weight and synthetic activity without affecting DNA levels.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results